Shares of Chembio Diagnostics Inc. (CEMI) are rising above 35% in pre-market today, after the company announced a worldwide strategic partnership with LumiraDx Ltd. to develop point-of-care diagnostic tests for the detection of the COVID-19 virus and IgM and IgG antibodies on both the LumiraDx and Chembio DPP platforms.
from RTT - Before the Bell https://ift.tt/2wSvuCc
via IFTTT
No comments:
Post a Comment